预约演示

更新于：2025-05-07

CD123

更新于：2025-05-07

基本信息

别名

CD123、IL-3 receptor subunit alpha、IL-3R subunit alpha

+ [8]

简介

Cell surface receptor for IL3 expressed on hematopoietic progenitor cells, monocytes and B-lymphocytes that controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells (PubMed:10527461). Ligand stimulation rapidly induces hetrodimerization with IL3RB, phosphorylation and enzyme activity of effector proteins such as JAK2 and PI3K that play a role in signaling cell proliferation and differentiation. Activation of JAK2 leads to STAT5-mediated transcriptional program (By similarity).

关联

109

项与 CD123 相关的药物

Tagraxofusp-ERZS

靶点

CD123

作用机制

CD123抑制剂

在研机构

The University of Texas MD Anderson Cancer Center [+2]

原研机构

Texas A&M University

在研适应症

Blastic浆细胞样树突状细胞肿瘤 [+8]

非在研适应症

淋巴母细胞淋巴瘤 [+7]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2018-12-21

Chlophedianol Hydrochloride

盐酸氯苯达诺

靶点

CD123

作用机制

CD123抑制剂

在研机构

Nippon Shinyaku Co., Ltd.

原研机构

Nippon Shinyaku Co., Ltd.

在研适应症

急性支气管炎 [+1]

非在研适应症

咳嗽 [+1]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2007-03-06

Talacotuzumab

靶点

CD123

作用机制

CD123抑制剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

102

项与 CD123 相关的临床试验

NCT06917105

/ Not yet recruiting临床1/2期IIT

Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies

This is an open-label, single-arm, exploratory clinical trial utilizing a "3+3" dose escalation followed by dose expansion to evaluate the safety, maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary efficacy of CD33/CD123/CLL-1 CAR-T cell therapy in patients with relapsed/refractory myeloid malignancies.
Part A: Dose Escalation Phase. Follows a "3+3" dose escalation design with four predefined dose cohorts: 0.2×10⁶, 0.5×10⁶, 1×10⁶, and 2×10⁶ CAR-positive cells/kg.Anticipated enrollment: 12-24 subjects.Primary objectives: Assess safety, tolerability, and determine MTD.Dose-limiting toxicity (DLT) observation period: 28 days post-infusion.
Part B: Dose Expansion Phase.Enrolls 21 additional subjects to receive CAR-T cell infusion at the recommended Phase 2 dose (RP2D) established in Part A.Primary objective: Further evaluate therapeutic efficacy.
Overall Study Objectives:Safety profile of CD33/CD123/CLL-1 CAR-T therapy.Efficacy endpoints (e.g., response rates, survival outcomes).Pharmacokinetic characterization of CAR-T cells (expansion/persistence).

开始日期2025-04-01

申办/合作机构

Hebei Taihe Chunyu Biotechnology Co., Ltd.

NCT06414681

/ Not yet recruiting早期临床1期

An Open Label Pilot Trial of the Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

The goal of this open-label, single-center, pilot trial is to test the combination of Tagraxofusp (TAG) with Pacritinib (PAC) in patients with intermediate-II or higher myelofibrosis (MF), who have had prior therapy with the approved JAK1/2 inhibitor or in which therapy with the approved JAK1/2 inhibitors is not appropriate, contraindicated or declined by the subjects.
The Primary Objective is to:
1. Characterized efficacy of the combination of Tagraxofusp and Pacritinib.
The Secondary Objective is to:
1. characterize the safety profile of the combination Tagraxofusp and Pacritinib.
2, Characterize the feasibility of the combination Tagraxofusp and Pacritinib. 3. Characterize hematologic improvement with the combination Tagraxofusp and Pacritinib.
4. Evaluate and compare the effect of Tagraxofusp and Pacritinib on participant reports of MF symptoms.
Exploratory:
Pharmacokinetic (PK) testing of Tagraxofusp and Pacritinib to assess clinical predictors of response.
Next Generation Sequencing (NGS) Testing to define the number and the allele burden of pathological mutations, as well as the changes over the course of therapy, both in regard to progression and response.
Blood will be collected and stored at KU BRCF for future study related PK analysis

开始日期2025-03-28

申办/合作机构

University of Kansas Medical Center

NCT06768476

/ Recruiting临床1期IIT

Phase I Trial of CART123 Cells Given in Combination With Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase I, open-label study to assess the safety, feasibility, pharmacokinetics, and preliminary efficacy of CART123 cells given in combination with ruxolitinib in patients with relapsed or refractory acute myeloid leukemia (AML). All subjects will receive a single infusion of CART123 cells following ruxolitinib administration and lymphodepletion. Ruxolitinib dosing will begin at initiation of lymphodepleting chemotherapy (Day -6 ±1d) and continue for up to 14 days post CART123 administration.

开始日期2025-03-01

申办/合作机构

University of Pennsylvania

[+1]

100 项与 CD123 相关的临床结果

登录后查看更多信息

100 项与 CD123 相关的转化医学

登录后查看更多信息

0 项与 CD123 相关的专利（医药）

登录后查看更多信息

1,778

项与 CD123 相关的文献（医药）

2025-06-01·Journal of Virus Eradication

Human CD123+AXL+ dendritic cells express Siglec1 that captures and transmits HIV-1 particles to the T cells

Article

作者: Cheng, Liang ; Zhang, Liguo ; Li, Guangming ; Yu, Haisheng ; Su, Lishan ; Cao, Yinghui

Human dendritic cells (DCs) are classified into three subsets based on their ontogeny, transcriptomes, and functions. During primary human immunodeficiency virus (HIV) infection, DCs in the peripheral tissues capture the HIV-1 particles, migrate to the lymph nodes, transfer the particles to CD4⁺ T cells, and initiate infection. However, the identity of the DC subset involved is yet elusive. Hitherto, a novel subset (AXL⁺DCs) has been identified in human blood, which is transcriptomically and functionally distinct from three known subsets. Compared to these, resting AXL⁺DCs express Siglec1 (CD169), capture HIV-1 particles in a CD169-dependent manner, and mediate transinfection. These results suggested that AXL⁺ DCs may facilitate HIV-1 transmission and the spread of very early-stage HIV infection in patients. Therapeutic strategies that target AXL⁺DCs or CD169 interaction with HIV-1 may provide pre-exposure protection during the initial stages of HIV-1 infection.

2025-06-01·Biomaterials

Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targeting

Article

作者: Wei, Xingyu ; Liu, Yongcan ; Yang, Jing ; Sun, Minghui ; Zhang, Ling ; Yuan, Zihao ; Li, Genyou ; Lin, Can ; Tang, Lisha ; Zhao, Wen ; Yang, Zesong ; Jin, Fangfang ; Wang, Xiaozhong ; Hu, Jiayuan ; Ren, Jun

Acute myeloid leukemia (AML) presents significant treatment challenges due to the severe toxicities and limited efficacy of conventional therapies, highlighting the urgency for innovative approaches. Organelle-targeting therapies offer a promising avenue to enhance therapeutic outcomes while minimizing adverse effects. Herein, inspired that primary AML cells are enriched with lysosomes and sensitive to lysosomophilic drugs (e.g., LLOMe), we developed a smart nanodrug (Cas-CMV@LM) including the engineered cell membrane vesicles (CMVs) nanocarrier and the encapsulated drug cargo LLOMe (LM). Briefly, the nanodrug with organ-cell-organelle cascade-targeting function could firstly home to the bone marrow guided by CMVs derived from CXCR4-overexpressing bone marrow mesenchymal stem cells (BMSC), subsequently target leukemia cells via CD33 and CD123 aptamers anchored on the vesicles, eventually precisely attack the lysosomes of leukemia cells. Consequently, Cas-CMV@LM specifically inhibited leukemia cell proliferation and triggered necroptosis in vitro. Importantly, the cascade-targeting nanodrug displayed high biosafety and significantly impeded leukemia progression in AML patient-derived xenograft (PDX) model. Collectively, this study provides a paradigm for precision leukemia treatment from the perspective of targeting organelle-lysosome.

2025-05-01·European Journal of Haematology

Atypical Hairy Cell Leukemia—The Current Status and Future Directions

Review

作者: Robak, Tadeusz ; Krawczyńska, Anna ; Robak, Marta ; Braun, Marcin ; Majchrzak, Agata

ABSTRACTHairy cell leukemia (HCL) is a rare, chronic lymphoid leukemia characterized by circulating lymphocytes with pale, hair‐like cytoplasmic projections, pancytopenia, marked monocytopenia, and splenomegaly. Classic HCL displays distinct morphological, immunophenotypical, and genetic features. Classic HCL cells exhibit central nuclei, abundant cytoplasm with hair‐like projections, and expression of CD20, CD22, CD11c, CD103, CD25, CD123, TBX21, annexin A1 (ANXA1), FMC7, CD200, and weak cyclin D1 (CCND1). While the vast majority of classic HCL cases harbor the BRAF V600E somatic mutation, rare examples have been reported without splenomegaly, with bulky lymphadenopathy, or with an atypical morphology, immunophenotype or genotype. This review analyzes the atypical clinical, morphologic, immunophenotypic, and genetic presentations associated with classic HCL. PubMed, Web of Science, and Google Scholar were searched for articles of hairy cell leukemia, including atypical morphology, atypical immunophenotype, atypical genotype, and rare symptoms. Publications from October 2004 to December 2024 were reviewed, with additional relevant studies obtained by reviewing references from selected articles.

412

项与 CD123 相关的新闻（医药）

2025-04-25

·GBIHealth

赛诺菲2025Q1财报：全球增长9.7%，中国市场下滑1.7%

药械追踪No.1 / 康方生物PD-1单抗安尼可在美获批，治疗鼻咽癌2025年4月25日，康方生物（9926.HK）宣布，派安普利单抗（商品名：安尼可）已获得美国食品药品监督管理局（FDA）批准上市，用于治疗复发或转移性鼻咽癌的一线治疗，以及以铂类为基础的至少一线化疗治疗失败后的治疗两项适应证。派安普利单抗是一款新型差异化PD-1单抗，由康方生物自主研发、并由康方生物与中国生物旗下正大天晴药业集团合资的天晴康方负责后续开发和商业化。其用于晚期鼻咽癌一线和二线后线治疗此前已在中国获得批准。Ⅲ期AK105-304研究和AK105-202研究的积极结果支持了FDA此次批准，此前FDA曾授予派安普利单抗治疗鼻咽癌的1项突破性疗法认定（BTD）、1项孤儿药资格认定（ODD）和1项快速通道资格（FTD）。->点击文末阅读原文，解锁完整双语新闻企业动态No.1 / 赛诺菲退还Innate CD123靶向ANKET药物相关权益2025年4月25日，Innate Pharma SA（（以下简称“Innate”）宣布，已与赛诺菲协商，对双方于2016年1月签署的研究合作与许可协议（以下简称“2016年协议”）进行重要调整，同时2022年研究合作与许可协议（以下简称“2022年协议”）保持不变。2016年协议允许赛诺菲利用Innate专有的多特异性抗体平台ANKET研发SAR’579/IPH6101，这是一款CD123 ANKET药物。本次协议调整后，赛诺菲将SAR’579/IPH6101的完整权益退还Innate。2024年4月，赛诺菲将SAR’579/IPH6101推进至II期临床阶段，双方后续将就正在进行的研究制定过渡计划。基于2016年协议，赛诺菲自Innate获得的另一项目SAR’514/ IPH6401（BCMA ANKET）将继续推进。赛诺菲计划提前终止SAR’514/ IPH6401用于复发或难治性多发性骨髓瘤患者的I/II期临床试验（临床试验登记号：NCT05839626），并将重新聚焦其用于自身免疫适应证的开发。此外，根据双方协商结果，赛诺菲可能通过增发新股的方式对Innate进行潜在投资，投资金额最高可达1500万欧元；股权投资的具体规模和价格将根据当前市场条件确定。ANKET是Innate的专有平台，用于开发下一代多特异性NK细胞衔接器。目前除了SAR’514/ IPH6401，赛诺菲和Innate还在合作开发B7-H3靶向的ANKET项目IPH62。根据2022年协议，赛诺菲仍保留选择一个新的ANKET靶点的权利。->点击文末阅读原文，解锁完整双语新闻No.2 / 甘李药业2024财报：增收16.77%至30.45亿元2025年4月25日，甘李药业（603087.SH）发布2024年财务业绩。公司全年实现营业收入30.45亿元，同比增长16.77%；归母净利润为6.15亿元，同比增长80.75%。期内研发投入6.46亿元，占营收比重21.20%报告期内，甘李药业国内外营业收入稳健增长。在中国市场，作为国产胰岛素领军企业，甘李药业在首轮集采中实现销量持续增长，接续集采申报的六款胰岛素产品全数中选，且所有参加组别均有A类中选产品，获得更高协议量的同时价格也适当回调。全年国内销售收入达25.18亿元，同比增长15.38%。在国际市场，公司通过了欧盟EMA上市批准前GMP检查，这也是国产胰岛素类似物注射液首次通过EMA的GMP检查，标志着公司已具备甘精胰岛素注射液、赖脯胰岛素注射液、门冬胰岛素注射液及预填充注射笔的欧盟商业化生产条件。报告期内，公司出口额持续攀升，国际收入达5.28亿元，同比增长23.89%。甘李药业在研管线中，博凡格鲁肽（GZR18）注射液已顺利完成中国II期临床研究并达到主要终点，在2型糖尿病患者及肥胖/超重受试者中均取得良好数据。另一款核心产品GZR4注射液（胰岛素周制剂）在中国2型糖尿病患者中开展的II期临床试验也达到了主要终点，在降低HbA1c方面优于德谷胰岛素（诺和达）；目前GZR4已启动3项中国III期临床研究，分别为SUPER-1（胰岛素初治）、SUPER-2（基础胰岛素经治）及SUPER-3（基础胰岛素联合餐时胰岛素强化治疗）。->点击文末阅读原文，解锁完整双语新闻No.3 / 德国默克拟以35亿美元收购SpringWorks近日，《华尔街日报》报道称，德国默克拟以35亿美元收购美国生物制药公司SpringWorks Therapeutics（简称“SpringWorks”）。SpringWorks股价周四下午上涨9.03%，至44.93美元。据知情人士透露，两家公司已就接近每股47美元的定价达成一致。如果谈判顺利，协议最早可能在下周一完成。SpringWorks于2023年底推出了第一款药物Ogsiveo（nirogacestat），这是一种口服γ分泌酶抑制剂，也是FDA批准的首个成人硬纤维瘤治疗药物。2024年，SpringWorks营收1.91亿美元，其中Ogsiveo贡献1.72亿美元。2025年初，SpringWorks第二款新药Gomekli（mirdametinib）获得FDA批准，这是一种口服小分子MEK抑制剂，用于治疗无法完全切除的患有1型神经纤维瘤病（NF1）且伴有症状性丛状神经纤维瘤（PN）的成人和儿童患者。->点击文末阅读原文，解锁完整双语新闻No.4 / 赛默飞世尔未来四年将在美追加20亿美元投资2025年4月25日，赛默飞世尔（Thermo Fisher Scientific Inc.，NYSE: TMO）宣布，未来四年将在美国追加20亿美元投资，以强化美国在生命科学领域的创新、制造与经济竞争力。投资计划具体包括：投入15亿美元资本支出，用于提升和扩大美国本土的制造业务；配套投入5亿美元研发资金，聚焦高影响力创新领域。目前，赛默飞世尔在美国37个州拥有64家制造工厂，提供生产分析仪器、专科诊断产品以及生命科学解决方案，并为制药创新企业提供合同研发与制造服务。未来四年，赛默飞世尔将继续扩大其在美国的影响力。->点击文末阅读原文，解锁完整双语新闻No.5 / 赛诺菲2025Q1财报：全球增长9.7%，中国市场下滑1.7%赛诺菲（纳斯达克代码：SNY）近日公布2025年第一季度财报（2025Q1）。公司全球净销售额达98.95亿欧元（约112.5亿美元，GBI计算），同比增长9.7%（按固定汇率计算，下同）。在成熟药物表现方面，过敏与哮喘重磅炸弹药物达必妥（度普利尤单抗）持续强劲增长，销售额同比增长20.3%至34.8亿欧元（39.6亿美元）。长效胰岛素来得时（甘精胰岛素）同比增长24.4%，达4.5亿欧元（5.12亿美元）。8款新上市药物合计贡献8.47亿欧元销售额，同比增长43.8%，其中：血友病疗法Altuviiio（重组凝血因子VIII）销售额达2.51亿欧元（2.85亿美元），同比增长100%，CEO保罗·哈德森称其有望成为公司下一款重磅炸弹药物。疫苗业务方面，销售额同比增长11.4%至13.3亿欧元（15.1亿美元）。其中，呼吸道合胞病毒（RSV）疫苗乐唯初（尼塞韦单抗）销售额2.84亿欧元（3.23亿美元），同比激增54.9%。从地区来看，美国市场为主要增长驱动力，收入同比增长15.4%至46.6亿欧元（53亿美元）；欧洲市场收入微增0.5%至20.4亿欧元（23亿美元）；世界其他地区收入达32亿欧元（36亿美元），同比增长8.4%；但中国市场（计入世界其他地区）收入同比下滑1.7%至7.01亿欧元（7.97亿美元）。公司财报电话会内容亮点之一是首席财务官Francois Rodger巧妙回避了针对美国加征关税潜在影响的提问，他表示：“目前公司对于美国加征关税的问题尚无具体信息可分享，但公司已考虑了所有可能的情景，必要时将适时通报进展”。赛诺菲2025年的业绩指引保持不变，预计全年收入将实现中高个位数百分比增长。->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ xujingou@baidu.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

财报孤儿药突破性疗法临床3期临床1期

2025-04-23

·生物制品圈

赛诺菲终止靶点CD123的开发协议，又反手拟进行1500万欧元战略投资

4月23日，生物制药公司 Innate Pharma 发布公告，宣布公司重新获得其CD123靶向 ANKET® (Antibody-based NK cell Engager Therapeutics) 药物 SAR’579/IPH6101 的全球权利，该药物目前正处于治疗急性髓系白血病 (AML) 的研发阶段。与此同时，赛诺菲亦有意向对 Innate Pharma 进行高达1500万欧元的战略股权投资。Innate Pharma与赛诺菲对2016年签署的研究合作和许可协议进行了调整，包括双方终止在 CD123 靶点药物上的合作、赛诺菲继续推进 BCMA 靶点药物在自身免疫性疾病领域的开发，以及赛诺菲有意对 Innate Pharma 进行战略投资。合作调整根据双方当前战略重点的调整，赛诺菲决定继续推进 SAR’514/IPH6401（BCMA ANKET®）在自身免疫性疾病领域的开发，而终止 2016 年协议中关于 SAR’579/IPH6101（CD123 ANKET®）的合作，Innate Pharma 将重新获得这款靶向 CD123 的 ANKET® 药物的全部权利。药物研发进展Sanofi 此前主导的 SAR’579 / IPH6101 的 1/2 期临床研究（NCT05086315）仍在进行，在 2024 年欧洲血液学协会（EHA）大会上公布的剂量爬坡部分的疗效和安全性数据显示出一定临床获益和持久反应。2024 年 4 月，Sanofi 已将 SAR’579 / IPH6101 推进至该试验的初步剂量扩展阶段，双方将就正在进行的研究制定过渡计划。战略投资意向赛诺菲有意向对 Innate Pharma 进行高达 1500 万欧元的新股投资，这笔潜在投资的规模和价格将根据当前的市场情况确定，并在市场条件满足的情况下进行。Innate Pharma 首席执行官 Jonathan Dickinson 对此表示欢迎，认为这将进一步验证公司在研发方面的创新和科学进展。其他合作安排尽管终止了 CD123 ANKET® 的合作，Sanofi 将继续根据 2016 年的许可协议，专注于 SAR’514/IPH6401（BCMA ANKET®）在自身免疫性疾病领域的开发。此前针对复发或难治性多发性骨髓瘤患者进行的 Sanofi 主导的 1/2 期临床研究（NCT05839626）将提前终止，以便将该项目重新聚焦于自身免疫性疾病。此外，Innate Pharma 的另一个基于 ANKET® 平台的 NK 细胞衔接器项目 IPH62（靶向 B7-H3）也在开发中，Sanofi 仍保留根据 2022 年研究合作和许可协议选择一个额外 ANKET® 靶点的权利，双方于 2022 年达成的研究合作和许可协议保持不变，Innate Pharma 仍有资格获得超过 10 亿欧元的研发和商业里程碑付款。赛诺菲终止与 Innate Pharma 在 CD123 靶向药物上的合作，同时又表示要对 Innate Pharma 进行战略投资，看似矛盾，实则是基于多方面战略考量：战略重点调整赛诺菲终止 CD123 靶点药物合作，是基于自身战略重点的变化。公司选择继续推进 SAR’514/IPH6401（BCMA ANKET®）在自身免疫性疾病领域的开发，将资源集中于更符合公司当下战略方向的项目上。这表明赛诺菲对研发资源进行了重新配置，以聚焦核心业务和有更大发展潜力的领域。认可创新价值赛诺菲有意对 Innate Pharma 进行战略投资，是对 Innate Pharma 在研发方面创新和科学进展的认可。Innate Pharma 的 ANKET® 技术平台具有一定的创新性和潜力，赛诺菲的投资意向可能是希望在未来能与 Innate Pharma 在其他项目或领域继续开展合作，分享其技术成果和研发收益。通过投资，赛诺菲可以保持与 Innate Pharma 的联系，关注其技术发展，为未来可能的合作或业务拓展奠定基础。降低风险与优化布局终止 CD123 靶点药物合作，可以使赛诺菲减少在该项目上的资源投入，降低研发风险。而对 Innate Pharma 进行战略投资，若未来 Innate Pharma 的其他项目取得成功，赛诺菲能够从中受益，实现投资回报，同时也有助于赛诺菲优化自身的产品布局和技术储备。参考资料：Innate Pharma官网.识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

细胞疗法临床1期引进/卖出临床研究

2025-04-23

·PipelineReview

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

MARSEILLE, France I April 22, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announce review of their January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) with Sanofi: As part of these discussions, Sanofi and Innate have agreed to a potential investment by Sanofi of up to €15M in new shares of Innate. The size and price of this equity investment will be determined on the basis of the ongoing market conditions, if they are satisfactory. The 2022 research collaboration and license agreement remain unchanged. “We are very pleased that Sanofi has chosen to further strengthen our relationship through a potential strategic equity investment in the company. This would further validate the innovation and scientific progress at Innate Pharma delivered by our research and development. We acknowledge Sanofi’s portfolio prioritization, and we are encouraged to see our ANKET ® platform being pursued in autoimmune indications. We will continue to evaluate, plan and execute next steps for our proprietary ANKET ® programs in oncology and beyond,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. SAR’579 (NCT05086315)/IPH6101 SAR’514/IPH6401: IPH62 and one additional target About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate’s portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X . SOURCE: Innate Pharma

引进/卖出免疫疗法临床研究